WFH SDM Tool: additional treatments and updated resources now live

WFH SDM Tool: additional treatments and updated resources now live

The World Federation of Hemophilia (WFH) is pleased to announce the latest release of the WFH Shared Decision-Making (SDM) Tool. The WFH SDM Tool is regularly updated—either on an annual basis or when new treatment options become available—to ensure that people with hemophilia, caregivers, and healthcare professionals have access to up-to-date treatment information and resources to support informed decision-making.

Also available in: Français Español

All fact sheets and treatment class tables on the WFH Shared Decision-Making (SDM) Tool have been updated to include new evidence for 2025, providing users with accurate, accessible, and evidence-based resources when considering treatment options.

Highlights of the latest release include:

Information on antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl, marstacimab, concizumab, and fitusiran are now included alongside other established therapies, giving people with hemophilia and clinicians a more comprehensive overview of the choices available. With fact sheets and comparative information on UHL and rebalancing therapies now fully integrated, the tool reflects the latest evidence and evolving treatment landscape.

The updated WFH SDM Tool is currently available in six languages—English, French, Spanish, Japanese, German, and Dutch—with Italian, Czech, Croatian, Arabic, and Danish planned for the near future. This ensures that users around the world can access the same high-quality information in their preferred language. The WFH is committed to expanding the tool’s reach through additional translations, supporting its vision of making shared decision-making a global standard of care.

Shared decision-making is central to personalized hemophilia care. By regularly updating the SDM Tool with new treatment classes, the WFH continues to help people with hemophilia and their healthcare team work together to identify treatment options that best align with individual needs, values, and contexts.

The WFH encourages all members of the hemophilia community to explore the updated tool and use it to support meaningful conversations about care.

The WFH thanks our Corporate Partners BioMarin Pharmaceutical Inc., CSL Behring, F. Hoffmann-La Roche, Novo Nordisk, Pfizer, Sanofi and Sobi.

We’ve accomplished a lot this year, we need your help to continue strong.

Would you like to read more about similar articles?

Disclaimer

The information on the WFH website is provided for general information purposes only. The WFH does not engage in the practice of medicine and under no circumstances recommends particular treatment for specific individuals. For diagnosis or consultation on a specific medical problem, the WFH recommends that you contact your physician or local treatment centre. Before administering any products, the WFH urges patients to check dosages with a physician or hemophilia centre staff, and to consult the pharmaceutical company’s printed instructions.

While every effort has been made to ensure the accuracy of the information on this site, the WFH does not guarantee the information is accurate, and is not responsible in any way whatsoever for damages arising out of the use of this website or any of the information contained herein.

Messages posted to WFH discussion forums, Facebook, Twitter, and other social media platforms do not represent the opinions of the World Federation of Hemophilia, its staff, or Board of Directors. The author of a message is solely responsibility for its content. Information posted on WFH social networks and platforms should never be a substitute for individualized professional medical advice, even when the author has medical qualifications or is considered an authority. Information posted to a discussion group should not be used to diagnose or treat a specific health problem without consulting a qualified healthcare professional. The WFH recommends that you contact your physician or local treatment centre if you have any individual questions or concerns.

References and links to other websites or references to other organizations, products, services, or publications do not constitute endorsement or approval by the WFH. The WFH is not responsible and assumes no liability for the content of any linked websites.

Fraud Alert

Unauthorized solicitations – Warning

The WFH has been made aware of various correspondences—circulated via e-mail and telephone—coming from individuals impersonating WFH staff or falsely stating that they are associated with the WFH. These correspondences, which may seek to obtain money using the name of someone affiliated with the WFH, are fraudulent and come from outside of our organization.

If you receive a suspicious solicitation, exercise extreme caution. In the case of an email, look at the email address to see if it looks suspicious (for example, all WFH emails come from @wfh.org).

We are asking you to remain vigilant, and if you have any doubts about the correspondence, please forward the email to the WFH at [email protected] or call +1 514-875-7944.